日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Acquired Resistance to Afatinib Mediated by EGFR T790M in Lung Adenocarcinoma Patients Harboring EGFR-KDD: A Case Report and Literature Review

EGFR T790M介导的肺腺癌患者对阿法替尼产生获得性耐药:病例报告及文献综述

Liu, Qian; Lv, Lu; Pang, Guanchao; Wang, Pingli

CD34 evaluation of microvasculature in lung adenocarcinoma and its microvascular density predicts postoperative tumor recurrence.

CD34 对肺腺癌微血管的评估及其微血管密度可预测术后肿瘤复发

Qiu Zijian, Wu Jiaji, Pang Guanchao, Xu Xia, Lin Jun, Wang Pingli

Risk factors of immune checkpoint inhibitor-related pneumonitis after neoadjuvant immunochemotherapy for resectable NSCLC

可切除非小细胞肺癌新辅助免疫化疗后免疫检查点抑制剂相关性肺炎的危险因素

Mao, Zhirong; Pang, Guanchao; Huang, Xiaojie; Chen, Xiuxiu; Wu, Jiaji; Xu, Xia; Teng, Zhihua; Tan, Yanbin; Wang, Pingli

Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice

真实世界中可切除非小细胞肺癌新辅助治疗的临床结果

Huang, Xiaojie; Pang, Guanchao; Mao, Zhirong; Li, Baizhou; Teng, Zhihua; Yang, Yan; Qiu, Zijian; Chen, Xiuxiu; Wang, Pingli

Integrase Interactor 1 (INI1) Deficiency in a Lung Cancer Patient Presents Nonresponse to Immunotherapy and Tazemetostat: A Case Report

肺癌患者整合酶相互作用蛋白1 (INI1) 缺陷导致免疫疗法和他泽美司他治疗无效:病例报告

Chen, Xiuxiu; Wu, Jiaji; Pang, Guanchao; Wei, Shumei; Wang, Pingli

Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer

新兴的基于血液的生物标志物可用于预测非小细胞肺癌对免疫检查点疗法的反应

Li, Shumin; Zhang, Chengyan; Pang, Guanchao; Wang, Pingli

Preoperative Risk Assessment of Lymph Node Metastasis in cT1 Lung Cancer: A Retrospective Study from Eastern China

cT1期肺癌淋巴结转移术前风险评估:一项来自中国东部的回顾性研究

Zhang, Chengyan; Pang, Guanchao; Ma, Chengxi; Wu, Jingni; Wang, Pingli; Wang, Kai